Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on March 11, 2021. The company is incorporated in Delaware and its common stock (CLRB) and warrants (CLRBZ) trade on the NASDAQ Capital Market. The filing serves as a Regulation FD disclosure regarding upcoming management presentations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces scheduled corporate communications.
Guidance, Outlook, and Management Commentary
James Caruso, President and CEO, is scheduled to present a company overview and participate in one-on-one meetings at the following conferences:
- Oppenheimer 31st Annual Healthcare Conference: March 16, 2021
- Maxim Group 2021 Emerging Growth Virtual Conference: March 17-19, 2021
A press release detailing these events is included as Exhibit 99.1. No specific financial guidance or risk factors are disclosed in this text.
Key Facts for Investor Verification
- Verify the content of the press release (Exhibit 99.1) for specific details on the company overview.
- Confirm the dates and access methods for the Oppenheimer and Maxim Group conferences.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.